Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Martinelli V et al. – The most serious risks of the drug are represented by potential cardiotoxicity and leukaemia, whose incidence seems to be higher than previously reported. Therefore, all potential serious adverse events should be carefully considered against the potential relevant benefits of MTX treatment on every single MS patient.


   

Today in Clinical Pharmacology...keeping you current

Ranolazine-related dyspnea on exertion
The American Journal of Geriatric Pharmacotherapy, 03/19/10

Treatment of Cluster Headache in Pregnancy and Lactation
Current Pain and Headache Reports, 03/19/10

A review of the effect of anticonvulsant medications on bone mineral density and fracture risk
The American Journal of Geriatric Pharmacotherapy, 03/19/10

Today in Neurology...keeping you current

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
Therapeutics and Clinical Risk Management, 03/19/10

Intracranial Neurostimulation for Pain Control: A Review
Pain Physician, 03/19/10

A Systematic Review on the Effectiveness of the Nucleoplasty Procedure for Discogenic Pain
Pain Physician, 03/19/10

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address